Experimental sites were pre-treated with terazosin (administered by iontophoresis for 10 minutes at 200 µA), and the same current intensity was passed through 0.9% saline to control for the nonspecific effects of iontophoresis. Pre-treatment with terazosin blocked vasoconstrictor responses to increasing doses of methoxamine, and also blocked vasodilatation several mm from the site of terazosin and methoxamine administration. These findings support the view that α 1 -adrenoceptors play a role in generating axon-reflex vasodilatation, and thus might contribute to local vascular disturbances in acute and chronic inflammation.
injury and inflammation (Ali et al., 1999; Nam et al., 2000; Dogrul et al., 2006) , and in experimental and clinical studies in humans (Torebjork et al., 1995; Fuchs et al., 2001; Mailis-Gagnon and Bennett, 2004; Jorum et al., 2007; Drummond, 2009 ).
Despite such findings, it has been assumed that sympathetic and nociceptive fibres do not interact directly under physiological conditions in human skin, as intradermal injection of noradrenaline or delivery through microdialysis fibres is painless and does not evoke axon-reflex vasodilatation (Zahn et al., 2004) .
Nevertheless, intradermal microdialysis of noradrenaline was found to decrease the temperature threshold of axon-reflex vasodilatation to local heat in healthy humans, and sympathetic blockade attenuated this response (Houghton et al., 2006; Hodges et al., 2008) . Furthermore, pre-treatment of the skin with local anaesthetic agent blocked the flare produced by noradrenaline when it was introduced into the skin by iontophoresis (Drummond and Lipnicki, 1999) . Together, these findings imply that noradrenaline facilitates axon-reflex vasodilatation initiated by heat or iontophoretic currents in humans, and thus might contribute to axon-reflex vasodilatation evoked by inflammatory mediators after nerve or tissue injury.
In rats, the adrenergic component of axon-reflex vasodilatation to capsaicin is mediated by α 1 -adrenoceptors (Lin et al., 2003) but whether this also applies in humans is uncertain because mechanisms of neurogenic inflammation differ between rat and human skin (Schmelz and Petersen, 2001; Sauerstein et al., 2000) . Thus, the aim of the present study was to determine whether α 1 -adrenoceptors also mediate axon-reflex vasodilatation in healthy human subjects. In particular, the aim was to establish whether prior administration of the α 1 -antagonist terazosin would block axon-reflex vasodilatation to the α 1 -agonist methoxamine. If so, this would support the view that α 1 -adrenoceptors play an important role in neurogenic inflammation in humans.
Method

Subjects
The sample consisted of 15 healthy volunteers (4 men and 11 women aged between 18 and 47 years) who were not taking prescription medication for any medical condition. They each provided informed consent for the procedures, which were approved by the Murdoch University Human Research Ethics Committee.
Procedures
The experiments were carried out in a temperature-controlled laboratory maintained at 22 + 1 o C. The first step in each experiment was to introduce terazosin into the skin to block α 1 -adrenoceptors. To determine whether the terazosin blockade was successful, vasoconstrictor responses to incremental doses of methoxamine were examined at terazosin-pretreated and control sites. Axon-reflex vasodilatation to methoxamine was examined adjacent to the site of terazosin pre-treatment and methoxamine administration in the final seven participants.
Pre-treatment with terazosin. Perspex iontophoresis capsules with an internal chamber diameter of 20 mm were attached with adhesive washers to the dorsal aspect of the left and right forearms, and 3 cm x 5 cm silver plates that acted as cathodes were attached to the wrists. Cotton swabs soaked with 0.9% saline were placed under the cathodes to enhance electrical contact with the skin. To ensure that the capsules adhered firmly and that good electrical contact was made, the forearm sites were shaved, if necessary, and cleaned with an isopropyl alcohol swab. Care was taken not to touch the skin with the razor while the hair was being removed. The perspex chambers were filled with a conducting medium (0.9% saline-control in one chamber and 10 mM terazosin hydrochloride in the other; Sigma, Sydney, Australia) and anodal currents of 0.2 mA were passed through the solutions to repel positively changed ions into the skin for 10 minutes (Drummond, 2002) . heating, a 5 µA anodal current was directed through the drug solution for 60 seconds to introduce positively-charged methoxamine ions into the skin. Skin blood flow was monitored during the iontophoresis and for another four minutes afterwards at the terazosin-pretreated and control sites. The same procedure was repeated at currents of 10 µA through to 320 µA, doubling the current intensity after each step. As current duration was held constant at 60 seconds, the dose of methoxamine introduced into the skin was proportional to the current intensity. Cathodes on the wrists completed the electrical circuits.
Effect of the terazosin pre-treatment on axon reflex vasodilatation to methoxamine. In the final seven participants, additional sites on the forearms were pre-treated with terazosin and 0.9% saline (control). The pre-treatment procedures were similar to those described above except that a central region of skin, 10 mm in diameter, was protected from the drug solution by a thick smear of petroleum jelly (Vaseline) ( Figure 1B ). Treated skin generally flushed after the iontophoresis of terazosin whereas the central region remained pale. After the pre-treatment, the petroleum jelly was removed and the subject rested quietly for 10 minutes to allow nonspecific vasomotor responses to the pre-treatment to subside. Iontophoresis capsules with a ring-shaped drug solution chamber (inner diameter 15 mm and outer diameter 19 mm) were then attached to the prepared sites and filled with 10 mM methoxamine solution. Adhesive tape was used to form a waterproof seal on each side of the drug solution chamber. The capsules were maintained at 32 o C (i.e., below the threshold for local heat-evoked vasodilatation) throughout the methoxamine iontophoreses that ranged in current strength from 5 µA to 320 µA, as described above. During each iontophoresis, positively-charged methoxamine ions were repelled away from the anode into the underlying skin for 60 seconds, followed by a 4-minute period of vascular monitoring. Skin blood flow was detected with a wide surface area laser Doppler flow probe positioned in the centre of the ring described by the iontophoresis chamber, 5-10 mm from the site of methoxamine administration over skin that had been covered with petroleum jelly during the pre-treatment ( Figure   1B ).
Data reduction and statistical approach
Skin blood flow was averaged for 1-2 minutes before the first iontophoresis to establish a baseline. As responses generally began during the 1-minute period of iontophoresis and peaked during the subsequent 4-minute period of monitoring, the mean response over the full 5-minute period was calculated. Blood flow was measured both in terms of mean flux (the low-frequency component of the signal reflecting tissue perfusion to a depth of 1-2 mm) and the amplitude of the high frequency pulsatile waveform (representing the beat-to-beat difference between arterial inflow and venous outflow). As skin blood flow was recorded in arbitrary rather than absolute units, responses were expressed as the percent change from levels at baseline.
Differences in response to methoxamine at the terazosin-treated and control sites were investigated in Drug Treatment (terazosin, control) x Dose (the seven current intensities ranging from 5 µA to 320 µA) repeated measures analyses of variance. Where appropriate, the Greenhouse-Geisser epsilon was used to adjust the degrees of freedom to correct for violations of the sphericity assumption. Differences in blood flow between treated and control sites at baseline were investigated with Student's paired t-tests.
Results
At baseline, neither mean flux nor pulse amplitude differed between the terazosin-treated and control sites in skin heated to 40 o C, although values were substantially higher in heated than unheated skin (Figure 2) . Similarly, blood flow did not differ significantly between control sites and sites that had been covered with petroleum jelly during the terazosin pre-treatment.
The terazosin pre-treatment blocked vasoconstriction to methoxamine ( Figure   3 ). In particular, the Drug Treatment x Dose interaction was significant both for mean flux [F(1.6,22.7) = 3.99, p<0.05] ( Figure 3A ) and pulse amplitude [F(2.2,31.1) = 3.50, p<0.05] (Figure 3B ), due to divergent responses between the treated and control sites at higher doses of methoxamine.
Similarly, the terazosin pre-treatment blocked signs of axon-reflex vasodilatation at higher doses of methoxamine (Figure 4) . Again, the Drug Treatment 
Adrenergic stimulation of sensory afferents
Although the means by which adrenergic agents affect axon reflex vasodilatation is uncertain, some findings suggest that direct stimulation of α 1 -adrenoceptors on neural membranes contributes to antidromic neuronal discharge and axon-reflex vasodilatation. Messenger RNA (mRNA) for α 1A -, α 1B -and α 2C -adrenoceptors has been demonstrated within rat dorsal root ganglion neurons (Nicholson et al., 2005) , and α 1 -adrenoceptor mRNA increased in the dorsal root ganglia of rats after spinal nerve ligation and sciatic nerve transection (Xie et al., 2001; Maruo et al., 2006) and in rats with streptozotocin-induced diabetic neuropathy (Lee et al., 2000) . At the physiological level, the α 1 -agonist phenylephrine was found to mobilize intracellular calcium in cultured dorsal root ganglion cells, and to liberate substance P from the distal terminals of nociceptive afferents in the urinary bladder (Trevisani et al., 2007) .
Other data suggest that adrenergic agents stimulate the release of intermediary agents which excite nociceptive afferents. For example, phenylephrine was found to increase the secretion of nerve growth factor, a potent nociceptive agent, from cultured vascular smooth muscle (Tuttle et al., 1993) , and to facilitate the nociceptive effects of adenosine triphosphate (Meisner et al., 2007) . In the rat kidney, increases in renal sympathetic nerve activity were associated with increases in afferent renal nerve activity; in particular, noradrenaline acted via α 1 -adrenoceptors to increase the synthesis and release of prostaglandin E 2 which, in turn, liberated substance P from nociceptive afferents (Kopp et al., 2007) .
Although the studies reviewed above were carried out on rats rather than humans, it is tempting to speculate that direct stimulation of neural α 1 -adrenoceptors or the release of intermediary agents such as prostaglandin E 2 evoked axon reflexes to methoxamine in the present study.
Role of inflammation
Iontophoretic currents induce an inflammatory response in human skin (Grossmann et al., 1995) which is mediated at the anode by prostaglandin synthesis (Tartas et al., 2005) . However, current-evoked prostaglandin production does not account entirely for axon-reflex vasodilatation to methoxamine, because the response was profoundly inhibited by pre-treatment with the α 1 -antagonist terazosin in the present study. The inflammatory mediators released by iontophoretic currents may disrupt the blood-nerve barrier, thereby increasing access to protected α 1 -adrenoceptors in cutaneous nerve fascicles (Drummond, 1998) . This could explain why the iontophoresis of adrenergic agonists evokes axon-reflex vasodilatation (Drummond and Lipnicki, 1999) whereas administration via intradermal microdialysis fibres does not (Zahn et al., 2004) .
Clinical implications
Although neurogenic inflammation is primarily protective, an abnormal excitability of this response could sensitize nociceptive afferents and promote chronic inflammation (Peters et al., 2006; Cunha et al., 2008) . The present findings suggest that α 1 -adrenoceptors contribute to this process by evoking axon-reflex vasodilatation.
During chronic inflammation, increased access to neural α 1 -adrenoceptors could establish a vicious circle between sympathetic neural discharge, neurogenic inflammation and pain. This might be important in genitourinary tract disorders (Trevisani et al., 2007) and in conditions such as complex regional pain syndrome, which is characterized by elevated levels of inflammatory mediators, enhanced axonreflex vasodilatation and signs of adrenergic supersensitivity in the affected limb (Schinkel et al., 2006; Wesseldijk et al., 2008; Weber et al., 2001; Birklein and Schmelz, 2008; Drummond et al., 1996; Arnold et al., 1993; Chemali et al. 2001; Jorum et al., 2007; Gibbs et al., 2008) . at sites pre-treated with the α 1 -antagonist terazosin or 0.9% saline-control (see Figure   1A ). The dose of methoxamine introduced into the skin was proportional to the iontophoresis current (measured in µA). Pre-treatment with terazosin blocked decreases in mean flux (A) and pulse amplitude (B) at higher doses of methoxamine (* difference between control and terazosin pre-treated site statistically significant, p<0.05). Skin blood flow increased above baseline at the terazosin-treated site after
